MA30220B1 - Forme cristalline du chlorhydrate de besipirdine, procede de preparation et utilisation de celle-ci - Google Patents

Forme cristalline du chlorhydrate de besipirdine, procede de preparation et utilisation de celle-ci

Info

Publication number
MA30220B1
MA30220B1 MA31178A MA31178A MA30220B1 MA 30220 B1 MA30220 B1 MA 30220B1 MA 31178 A MA31178 A MA 31178A MA 31178 A MA31178 A MA 31178A MA 30220 B1 MA30220 B1 MA 30220B1
Authority
MA
Morocco
Prior art keywords
preparation
following
besipirdine
crystalline form
exhibits
Prior art date
Application number
MA31178A
Other languages
English (en)
Inventor
Hugues Bienayme
Jacques Ferte
Original Assignee
Urogene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene filed Critical Urogene
Publication of MA30220B1 publication Critical patent/MA30220B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORME CRISTALLINE DU CHLORHYDRATE DE LA BESIPIRDINE, PROCEDES DE PREPARATION ET UTILISATIONS Forme cristalline du chlorhydrate de la besipirdine (Forme I) répondant à la formule A suivante : ladite forme étant caractérisée par au moins l'une des propriétés physico-chimiques suivantes : a) en FTIR, elle présente au moins les bandes d'absorption du spectre infrarouge suivantes : 778, 1198, 1121 et elle ne présente pas les bandes d'absorption du spectre infrarouge suivantes : 3395, 1583, 732, lesdites bandes étant exprimées en cm-1 à ± 5 cm-1 b) en PXRD, elle présente au moins les raies du diffractogramme suivantes correspondant aux raies les plus intenses et dont l'intensité n'est ci-après donnée qu'à titre indicatif : Angle (2thêta) 12,61 14,11 18,98 19,93 21,03 25,13 25,91 Intensité (%) 77,13 71,82 73,00 67,21 61,08 60,44 100,00 c) en DSC, elle présente au moins un pic endothermique à 187,3 ± 2,0°C, et une enthalpie de fusion (delta)H de 130,4 2,0 J/g. L'invention concerne aussi des procédés de préparation de la forme I, ainsi que ses applications en urologie.
MA31178A 2006-02-20 2008-08-15 Forme cristalline du chlorhydrate de besipirdine, procede de preparation et utilisation de celle-ci MA30220B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0601468A FR2897614B1 (fr) 2006-02-20 2006-02-20 Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations
US78715706P 2006-03-30 2006-03-30

Publications (1)

Publication Number Publication Date
MA30220B1 true MA30220B1 (fr) 2009-02-02

Family

ID=37309765

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31178A MA30220B1 (fr) 2006-02-20 2008-08-15 Forme cristalline du chlorhydrate de besipirdine, procede de preparation et utilisation de celle-ci

Country Status (16)

Country Link
US (1) US20090048304A1 (fr)
EP (1) EP1996575A2 (fr)
JP (1) JP2009527544A (fr)
KR (1) KR20080106232A (fr)
CN (1) CN101384584A (fr)
AU (1) AU2007219157A1 (fr)
BR (1) BRPI0707997A2 (fr)
CA (1) CA2642687A1 (fr)
FR (1) FR2897614B1 (fr)
IL (1) IL193191A0 (fr)
MA (1) MA30220B1 (fr)
MX (1) MX2008010659A (fr)
NO (1) NO20084010L (fr)
RU (1) RU2008133759A (fr)
WO (1) WO2007096777A2 (fr)
ZA (1) ZA200806876B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019007285A1 (fr) * 2017-07-03 2019-01-10 山东丹红制药有限公司 Forme cristalline et forme amorphe de chlorhydrate d'analogue de dézocine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
DE69621617T2 (de) * 1995-07-27 2003-01-02 Aventis Pharmaceuticals Inc., Bridgewater Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva
AR046041A1 (es) * 2003-10-03 2005-11-23 Aventis Pharma Inc Procedimiento para la preparacion de compuestos heterociclicos n-amino sustituidos

Also Published As

Publication number Publication date
AU2007219157A1 (en) 2007-08-30
ZA200806876B (en) 2009-10-28
US20090048304A1 (en) 2009-02-19
NO20084010L (no) 2008-11-19
MX2008010659A (es) 2008-09-01
WO2007096777A3 (fr) 2008-01-17
FR2897614B1 (fr) 2008-05-23
EP1996575A2 (fr) 2008-12-03
BRPI0707997A2 (pt) 2011-05-17
IL193191A0 (en) 2009-08-03
JP2009527544A (ja) 2009-07-30
RU2008133759A (ru) 2010-03-27
CN101384584A (zh) 2009-03-11
FR2897614A1 (fr) 2007-08-24
WO2007096777A2 (fr) 2007-08-30
KR20080106232A (ko) 2008-12-04
CA2642687A1 (fr) 2007-08-30

Similar Documents

Publication Publication Date Title
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
MY143249A (en) 4-substituted pyrrolidin-2-ones and their use
WO2007120647A3 (fr) Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
WO2005063254A3 (fr) Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
MA29909B1 (fr) Derives de pyridazine
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
BRPI0507617A (pt) antagonistas de receptor de quimiocina
MA30686B1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase.
ATE482947T1 (de) Neues salz und polymorph des dpp-iv-hemmers
WO2004048345A3 (fr) Composes destines au traitement de l'obesite
TW200728307A (en) Novel spirochromanone derivatives
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA31884B1 (fr) Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
TN2009000484A1 (en) Substituted oxazolidinones and the use thereof
EP1951686A4 (fr) Dérivés de quinazoline en tant qu'inhibiteurs multiplex et méthode de synthèse desdits dérivés
MA30819B1 (fr) Nouvelle diphenylazetidinone substituee par l'acide piperazin-1-sulfonique et presentant des proprietes pharmacologiques ameliorees
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MA30959B1 (fr) Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
MX2008010035A (es) Compuestos de n-hidroxiacrilamida.
WO2008021463A3 (fr) Analogues de diaryl[a,d]cycloheptène à substitution amino, utilisés comme agonistes muscariniques et méthodes de traitement de troubles neuropsychiatriques
WO2007079214A3 (fr) Antagonistes du recepteur de la prokineticine 2